EMA’s CHMP to monitor Genzyme manufacturing improvements
This article was originally published in The Gold Sheet
At its May 17-20 monthly meeting, the European Medicines Agency's Committee for Medicinal Products for Human Use requested Genzyme to carry out a risk assessment of its manufacturing processes, and to use that assessment to develop a detailed plan for improvement. The committee wants regular progress reports on implementation, it told Genzyme officials who made a presentation about the company's management and quality assurance systems at the meeting
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.